The poop on Glaxo chimp virus project

From ANIMAL PEOPLE,  July-August 2013:

LONDON––GlaxoSmithKline,  the largest British pharmaceuticals maker,  “is betting on a new vaccine technology based on chimpanzee viruses by acquiring Swiss-based Okairos for 250 million euros ($321 million),”  Ben Hirschler of Reuters reported on May 29,  2013.   As no European nation is known to currently house a chimp research lab,  this occasioned questions from ANIMAL PEOPLE.  “This area of work has no implications for research on chimpanizes themselves,”  responded GlaxoSmithKline global external communications manager Eleanor Bunch.   “The scientists actually use chimpanzee stool samples for their research, which they collect from zoos.”